Skip to content
TrialScanner

NCT02795676

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

Phase 3CompletedPLXLead

Registry record

Lead sponsor
Protalix
Conditions
Fabry Disease
Primary completion
Oct 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02795676 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02795676: Study of the Safety and... | TrialScanner